TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Born after 1968~* Good general health~* Available for the duration of the trial~Exclusion Criteria:~* Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease~* Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study~* Liver, renal, or hematologic disease~* Alcohol or drug abuse within 12 months of study entry~* History of severe allergic reaction or anaphylaxis~* Current asthma or reactive airway disease~* History of Guillain-Barre syndrome~* HIV-1 infected~* Hepatitis C virus infected~* Positive for hepatitis B surface antigen (HBsAg)~* Known immunodeficiency syndrome~* Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical corticosteroids are not excluded.~* Live vaccine within 4 weeks of study entry~* Killed vaccine within 2 weeks of study entry~* Absence of spleen~* Blood products within 6 months of study entry~* Current smoker~* Have traveled to the Southern Hemisphere or Asia within 30 days prior to study entry~* Have traveled on a cruise ship within 30 days prior to study entry~* Work in the poultry industry~* Investigational agents within 60 days prior to study entry, or currently participating in another investigational vaccine or drug trial~* Allergy to eggs or egg products~* Purified protein derivative (PPD) positive (positive tuberculosis \[TB\] test)~* Family member with immunodeficiency~* Other condition that, in the opinion of the investigator, would affect the participant's participation in the study~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops.
- 2 (Type: EXPERIMENTAL): One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20\~85~* Acute period (ischemic stroke confirmation on DWI or TIA within 14 days after symptom onset)~* Below 20 point of initial NIHSS score within 14 days after stroke onset and enrolment.~* Confirmation of atherosclerotic or steno-occlusive stroke mechanism (proximal cerebral arteries) on CTA or MRA .~* At least hemodynamically, perfusion status of a candidate is stage II or III (decrease of regional Cerebral blood flow on CBF map), moyamoya disease~* If female then not of childbearing potential~* Informed consent~Exclusion Criteria:~* Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH), arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm~* Treated with a thrombolytic \<24 hours (if \>24 hours and excluded ICH then eligible)~* Score \>=1 on the NIHSS item 1a~* Pre-stroke mRS score \<2~* Uncontrolled hypertension(irregularity systollic BP \> 150mmHg~* Previous treatment with erythropoietin~* At screening: Hemoglobin \>14 g/dl, prolonged PT or PTT, serum Cr \>2.0 ,mg/dl, BUN \>40, thrombocytopenia or neutropenia as defined by the lower limit of normal for the platelet count or white blood cell count, respectively (absolute neutrophil count of \> 1800/mm3 required for participation), or \> 2 times of normal on liver function tests (SGOT, SGPT, total bilirubin)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
- Group B (Type: NO_INTERVENTION): mechanical barrier disruption procedure Drug: no-specific intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Females aged 25-60~2. BMI 28-35 kg/m2~3. No known diagnosis of diabetes~4. No known diagnosis of coronary heart disease~5. Self-described sedentary lifestyle with minimal regular cardiovascular exercise (no more than 1 hour per week)~6. Stable weight (variation \< 3 kg within 6 months of screening visit)~7. Ability to give informed consent~8. Ability to follow verbal and written instructions~9. Use of medically approved form of contraception (monophasic oral contraception, intra uterine device, surgical sterilization or 2 combined barrier methods)~10. Nonsmoker (tobacco, marijuana)~11. Outpatient visits every 2 weeks throughout the study period are required. While most of these visits are short (15 minutes)ability to commute to the performance site in Boston, on a regular basis, is necessary.~Exclusion Criteria:~1. Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria~2. Coronary heart disease (history of myocardial infarction or unstable angina pectoris)~3. Uncontrolled hypertension hypertension (BP \> 150/90 mmHg on or off antihypertensive medication)~4. Uncontrolled dyslipidemia (LDL \> 200 or TG \> 400 on or off lipid lowering medication)~5. Tobacco, marijuana or intravenous drug use~6. Shift workers (night shift or alternating day/night shifts)~7. Recent weight loss (\> 3 kg within 4 months of the screening visit)~8. Gastroparesis~9. Inflammatory bowel disease~10. Malignancy treated with chemotherapy within the past 3 years~11. History of pancreatitis~12. Depression requiring hospitalization or diagnosis of psychosis~13. Renal insufficiency (creatinine clearance \< 50 ml/min)~14. Transaminases \> 2x above the normal range~15. Pregnancy within 6 months of the screening visit~16. Breastfeeding~17. Failure to use medically approved contraceptive methods~18. History of an eating disorder (anorexia, bulimia or laxative abuse)~19. History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)~20. New diagnosis of hypo or hyperthyroidism within 1 year of screening visit~21. Previous participation in a clinical study with exenatide~22. Presence or history of allergic reaction to multiple drugs

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Exenatide First (Type: PLACEBO_COMPARATOR): Started on Exenatide, 3 week washout, start placebo
- Placebo First (Type: EXPERIMENTAL): Started on placebo, 3 week washout, start exenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson'd Disease in accordance with the United Kingdom (UK) Brain Bank Criteria~* Hoehn \& Yahr scores of II-IV~* subjective report of experiencing at least 1hr/day (two, half-hour periods) of ON time with troublesome Levodopa-Induced Dyskinesia (LID)~* ambulation with or without aids (e.g., walker or cane)~* ≥30 days of a stable regimen of anti-Parkinson's medications that includes a levodopa dose administered ≥3 times daily~* a stable dose of levodopa throughout the study~* no amantadine for a minimum of 30 days prior to enrollment in the study~Exclusion Criteria:~* neurological or musculoskeletal disorders~* orthostatic hypotension at screening (defined as a drop of ≥20mm mercury (HG) systolic and ≥10mm HG diastolic at 2 or 5 minutes of quiet standing after 5 minutes of supine rest)~* a major psychotic disorder~* contraindication to GOCOVRI™ at time of screening, especially renal impairment estimated by glomerular filtration rate (eGFR) \< 50 ml/min/1.73 m2) as impaired renal function can increase the chances of adverse reactions to the study drug~* mild to severe cognitive impairment as measured by Montreal Cognitive Assessment (MoCA) score ≤ 23~* concurrent use of immediate release amantadine~* are pregnant or plan to become pregnant~* an implanted deep brain stimulator

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GOCOVRI Treatment (Type: EXPERIMENTAL): All participants will have gait, balance, dyskinesia assessed before and after receiving GOCOVRI (274 mg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria:~  * No radiographic evidence of disease~ * Stable disease, defined as no tumor progression within the past 3 months~* Previously treated with 1 course of localized or whole brain radiotherapy of at least 3,000 cGy at least 6 months before study registration~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 70-100%~Life expectancy~* At least 30 weeks~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No concurrent chemotherapy~Endocrine therapy~* Concurrent steroid therapy allowed if on stable or decreasing dose~Radiotherapy~* See Disease Characteristics~* No concurrent cranial radiotherapy~Surgery~* No concurrent surgery~Other~* More than 3 months since prior donepezil or EGb761~* No concurrent donepezil (group 2 only)~* No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)~* No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or enoxaparin) (group 2 only)~* No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)~* No other concurrent therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Written informed consent~* Patients undergoing their first or second IVF-ET cycle~* Age 18-45 years~* Use of Ovitrelle for final follicular maturation and luteinization~* Fresh or Frozen day-5 blastocysts transrer (Autologus or Egg donation)~Exclusion criteria:~* Gestational surrogacy (patient's eggs used for pregnancy in a surrogate mother)~* Canceled IVF cycles~* GnRH agonist triggering cycles in the case of fresh ET.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pain With Radiesse® With Lidocaine for Nasolabial Folds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is at least 18 years of age~* Is a candidate for nasolabial fold treatment using Radiesse~* Has approximately symmetrical nasolabial folds~* Understands and accepts the obligation not to receive any other facial procedures in the lower half of the face for 1 month~Exclusion Criteria:~* Has received any type of treatment or procedures including surgery in the nasolabial folds~* Has received neurotoxin, hyaluronic acid, calcium hydroxylapatite (CaHA) or collagen injections in the lower half of the face within past 6 months~* Has received polylactic acid, polymethyl methacrylate (PMMA), silicone or any other permanent filler in the lower half of the face~* Has nasolabial folds that are too severe to be corrected in one treatment session~* Has any history of hypersensitivity to lidocaine or anesthetics of the amide type

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Radiesse® Mixed with Lidocaine (Type: EXPERIMENTAL): Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
- Radiesse® without Lidocaine (Type: ACTIVE_COMPARATOR): Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 and\<45 years old.~2. Female patients with documented diagnosis of POF: \<40 years old, at least 4 months of amenorrhea not due to pregnancy, two FSH levels above 40 IU/L, at least one month apart.~3. Not in other trial within 3 months prior to the start of this trial.~4. Willing to participate in this trial and to give informed consent/assent before any procedures are performed in this trial.~Exclusion Criteria:~1. History of, or evidence of current malignancy within the past 5 years.~2. Severe functional impairment of vital organs.~3. Abnormal karyotype.~4. Coagulation disorders.~5. Severe pelvic adhesions.~6. Uncontrolled acute or chronic gynecologic inflammation.~7. Congenital adrenal cortical hyperplasia.~8. Cushing's syndrome.~9. Thyroid dysfunction.~10. Pituitary adenoma.~11. Pituitary amenorrhea or Hypothalamic amenorrhea.~12. Thrombophlebitis, venous thrombosis or artery thrombosis.~13. History of Oophorocystectomy.~14. Currently pregnant or breast-feeding.~15. Currently receiving other treatment that might affect the efficacy and safety of stem cells.~16. History of severe drug allergy.~17. Active infection detected by chest X-ray/CT.~18. HIV, TPAb positive.~19. Mental illness.~20. Currently participating in any other clinical trial that uses interventional drugs or examinations.~21. Patients that are deemed, by the investigator, inappropriate to participate in this trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- hAECs transplantation (Type: EXPERIMENTAL): To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of POF patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mars Flavanol Exercise and Cognitive Function Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 50-75~2. English-speaking~3. Ambulatory~4. BMI \< 32~5. Post-menopausal (women only), no estrogen replacement therapy~6. VO2max \< 36 and 33 ml/kg/min for men age 50-59 and 60-69 respectively; \< 29 and 27 ml/kg/min for women age 50-59 and 60-75 respectively.~7. Baecke Physical Activity Sports Score ≤ 2~8. Medical clearance to participate in the study (normal serum electrolyte, BUN, creatinine levels, normal blood pressure and resting cardiogram)~Exclusion Criteria:~1. Use of psychotropic medications~2. Current psychiatric disorder~3. Any condition for which aerobic training is counter-indicated~4. Habitual consumers of dietary or herbal supplements, including Gingko, flavonoid, and dietary herbal or plant extracts~5. Lactose Intolerance~6. Individuals who report directly to any of the study investigators~7. Diabetes~Exclusion Criteria (MRI-related)~1. Cardiac Pacemaker~2. Internal Pump~3. Insulin Pump~4. Tattoo eyeliner~5. Wire Sutures~6. Internal Metal Objects~7. Metal Slivers in Eye~8. Prosthesis~9. Hearing Aid Implants~10. Neurostimulator~11. Metal Fragments~12. Brain Aneurysm Clips~13. Vascular Clips~14. Breast Expander~15. Vena Cava Filter~16. Heart Valve~17. Metal Stents~18. Asthma~19. Hay-Fever~20. Sickle Cell Disease~21. Kidney Disease~22. Pregnant

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- exercise, dietary intervention (Type: ACTIVE_COMPARATOR): aerobic training and flavanol containing food product for 12 weeks
- no exercise, dietary intervention (Type: ACTIVE_COMPARATOR): wait list control plus flavanol containing food product for 12 weeks
- exercise, food product lacking flavanol (Type: ACTIVE_COMPARATOR): aerobic training plus food product without flavanol for 12 weeks
- wait list control food additive without flavanol (Type: PLACEBO_COMPARATOR): wait list control plus food product without flavanol for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes Mellitus~* 18-46 years of age~* Residual C-peptide production during screening~* Positive for at least one islet autoantibody: insulin (if only insulin autoantibody positive, determination must be within two weeks of insulin initiation), GAD-65, IA-2 or ZnT8~* Positive for at least one gene encoding HLA-DQ8 (DQB\*0302)~* No history of difficult to control hypertension (defined as requiring \> 2 anti-hypertensive medications)~* Agree to intensive management of diabetes with an HgbA1c goal of \< 8.0%~* If female: (a) surgically sterile or (b) postmenopausal or (c) if of reproductive potential, willing to use medically acceptable birth control (e.g. female hormonal contraception, barrier methods or sterilization.) until study completion~* If male and of reproductive potential, willing to use medically acceptable birth control until study completion, unless the female partner is postmenopausal or surgically sterile~Exclusion Criteria:~* Unable or unwilling to comply with the requirements of the study protocol~* No HLA-DQ8 gene (DQB\*0302)~* Difficult to control hypertension (defined as requiring \> 2 anti-hypertensive medications)~* History of postural hypotension or Addison's disease~* Body Mass Index (BMI) \> 30 kg/m2~* Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days~* Administration of an experimental agent for T1D at any time or use of an experimental device for T1D within 30 days of screening, unless approved by the study PI~* History of any organ transplant, including islet cell transplant~* Active autoimmune or immune deficiency disorder (e.g. sarcoidosis, rheumatoid arthritis)~* Anticipated pregnancy during the 12 week study period~* Any social or medical condition that would, in the opinion of the investigator, prevent complete participation in the study or that would pose a significant hazard to the subjects' participation~* History of active substance abuse within 12 months of screening~* A psychiatric or medical disorder that would prevent giving informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Study group (Type: EXPERIMENTAL): All participants selected to continue with Methyldopa administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete